Chemokines and chemokine receptors are extensively and broadly involved in cancer metastasis. Previously, we demonstrated that epigenetic silencing of the chemokine CXCL12 sensitizes breast and colon cancer cells to endocrine signaling and metastasis to distant tissues. Yet, the precise mechanism whereby CXCL12 production by tumor cells regulates dissemination remains unclear. Here, we show that administration of CXCL12 extended survival of tumorbearing mice by potently limiting metastasis of colorectal carcinoma or murine melanoma. Because secreted CXCL12 is a mixture of monomeric and dimeric species in equilibrium, oligomeric variants that either promote (monomer) or halt (dimer) chemotaxis were used to dissect the mechanisms interrupting carcinoma metastasis. Monomeric CXCL12 mobilized intracellular calcium, inhibited cAMP signaling, recruited β-arrestin-2, and stimulated filamentous-actin accumulation and cell migration. Dimeric CXCL12 activated G-protein-dependent calcium flux, adenylyl cyclase inhibition, and the rapid activation of ERK1/2, but only weakly, if at all, recruited arrestin, stimulated actin polymerization, or promoted chemotaxis. NMR analyses illustrated that CXCL12 monomers made specific contacts with CXCR4 that were lost following dimerization. Our results establish the potential for inhibiting CXCR4-mediated metastasis by administration of CXCL12. Chemokine-mediated migration and β-arrestin responses did not dictate the antitumor effect of CXCL12. We conclude that cellular migration is tightly regulated by selective CXCR4 signaling evoked by unique interactions with distinct ligand quaternary structures.
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malignancy | functional selectivity | cellular idling | cancer therapeutics | chemokine oligomer C hemokines are chemoattractant cytokines that bind G-protein-coupled receptors and are mediators for many physiological processes including cell trafficking, angiogenesis, and embryogenesis (1) (2) (3) . Chemokine receptor signaling is linked with cancer metastasis as well as infiltration of tumor-associated immune cells, neoangiogenesis, and proliferation (4, 5) . Chemokines as primary mediators of metastasis were first identified by Muller and colleagues who implicated the chemokine receptor CXCR4 in tumor cell trafficking (6) (7) (8) . At least 23 different cancers have been shown to express elevated levels of CXCR4, sensitizing these cancers to CXCL12 gradients in distant tissues (9) . CXCL12 is constitutively expressed in the bone marrow, lungs, and liver, which are common tissues of metastatic growth. Efforts to block metastatic dissemination have mainly used small molecule antagonists of CXCR4 (10) to limit cancer malignancy (11, 12) . However, this avenue has proven difficult to move into the clinic (5, 12) , suggesting alternative strategies to interfere with CXCR4-guided metastatic homing (for example, by the use of agonists rather than antagonists) are required. Our previous data indicate that epigenetic silencing of the Cxcl12 promoter enhances metastasis of colonic and mammary carcinoma, implicating the chemokine ligand as a key variable governing metastatic potential (13) (14) (15) .
Chemokines coordinate cell migration within the context of stable adhesion to surrounding cells or extracellular matrix. A paradox of chemokines is that chemotaxis, but not proximal intracellular signaling, exhibits a biphasic response over a limited concentration range (16, 17) . Chemokine ligands exist as a mixture of monomeric and higher-order species (18) . We discovered that changes in the oligomeric state of CXCL12 dictated the migratory outcome of monocytic cells in vitro, with monomer, but not dimer, inducing cellular migration (17) . Congruently, restoration of CXCL12 expression in colonic and mammary carcinoma cells markedly reduced their metastatic potential in vivo (14, 15) , in part, through increased sensitivity to detachment-induced cell death (15, 19) . We therefore speculate that local CXCL12 secretion acts as a tumor suppressor, preventing metastasis by shielding the primary tumor from remote chemotactic gradients. Here, we show that administration of wild-type CXCL12, a monomeric variant, or a constitutively dimeric mutant inhibits hepatic metastasis of colorectal carcinoma. Interestingly, dimeric CXCL12 exhibited receptor interactions, downstream signaling, and migration responses distinct from the monomeric chemokine. These data suggest the oligomeric states of CXCL12 mediate distinct biological effects through the same receptor.
Results

CXCL12 Treatment Blocks Colonic Carcinoma
Metastasis. Previously, we demonstrated that colon cancer cells reexpressing CXCL12 had reduced primary tumor growth and hepatic metastasis, in part through elevated detachment-induced cell death termed anoikis (13, 15, 19) . Here, we administered exogenous CXCL12 to immunodeficient mice orthotopically engrafted with human colonic carcinoma cells stably expressing firefly luciferase. To further dissect the roles for the monomeric and dimeric chemokine in metastasis, we used previously engineered CXCL12 variants (17) . Mice were treated with intraperitoneal injections of wild-type (CXCL12 WT ), preferentially monomeric (CXCL12 H25R ) (18) , or constitutively dimeric (CXCL12 2 ) (17) chemokine. Because our prior work indicates metastasis is markedly diminished in colon cancer cells (13) engineered to produce endogenous CXCL12 (CXCL12-Luc), those cells were used as a positive control (15, 19) . As shown in Fig. 1A , treatment with each of the three CXCL12 proteins improved survival. Biophotonic imaging indicated little change in overall tumor formation between CXCL12 variants (Fig. 1B) . Quantification of those data confirmed that observation, with little difference in whole body (Fig. 1C) or ex vivo primary tumor luminescence between any of the treatment groups. However, as highlighted in Fig. 1 B and E, ex vivo examination revealed markedly decreased tumor numbers in the liver of treated mice, suggesting the survival benefit reflected decreased metastasis. Indeed, administration of exogenous CXCL12 proteins was comparable to that of CXCL12 Luc cells in decreasing metastasis and improving survival.
Next, we tested the CXCL12 variants across a range of concentrations. Mice orthotopically engrafted with HCT116 cells were treated with 0.5-, 5-, or 50-μM doses of CXCL12 WT or CXCL2 2 . Overall tumor burden was markedly diminished in animals treated with titrated doses of chemokine ( Fig. 2A) . Ex vivo quantification revealed that CXCL12 WT or CXCL12 2 significantly decreased hepatic metastases at 5 and 50 μM, while the dimer also decreased metastasis at 0.5 μM (Fig. 2B ). Wild-type and monomer CXCL12 were unable to inhibit liver metastasis at the lowest concentration (Fig. S1 ). We next tested if this response was limited to colonic carcinoma cells. CXCR4 enhances metastatic implantation of B16 murine melanoma cells to the lungs (20) . CXCR4 expression was first confirmed in transfected B16 melanoma cells (Fig. 2C) . Preincubation of those cells with the optimal 5-μM dose of CXCL12 2 abrogated pulmonary melanoma metastasis ( Fig. 2 D and E) . Together, these data indicate that CXCL12 limits the ability of either orthotopic colonic or intravenously implanted melanoma cells to metastasize. Increased potency of CXCL12 2 suggested the different oligomeric states of the chemokine inhibited metastasis by distinct mechanisms.
CXCL12 Monomers and Dimers Exert Opposing Effects on Migration.
To confirm the specific impact of CXCL12 variants on colorectal cancer cells, we examined migration in cell culture systems. CXCL12 WT and CXCL12 H25R induced HCT116 chemotaxis ( Fig. 3A) and HT29 epithelial sheet migration (Fig. 3B) . However, neither 10-nM CXCL12 2 or 1,000-nM CXCL12 WT was able to stimulate migration ( Fig. 3 A and B and Fig. S2 A and B) . Native PAGE revealed the accumulation of homodimers at increasing concentrations of CXCL12 WT , consistent with the notion that the lack of migration reflects formation of nonmotogenic CXCL12 dimers (Fig. S2C ). Migration differences were not due to alterations in growth or programmed cell death because cell proliferation and apoptosis were not altered by CXCL12 variant stimulation (Fig. S3) . Further, CXCL12 2 competitively blocked CXCL12 WT -mediated (Fig. 3C ), but not CXCL8-induced, carcinoma migration (Fig. S4) .
Because cytoskeletal rearrangement and formation of newly branched filamentous-actin (F-actin) are required for migration, we visualized actin polymerization in cells stimulated with CXCL12 variants. Lamellipodia formation and F-actin were elevated in HCT116 cells treated with motogenic 10-nM CXCL12 WT or CXCL12 H25R but unchanged by 10-nM CXCL12 2 or 1,000-nM CXCL12 WT ligands ( Fig. 3 D and E) . Activated chemokine receptors undergo phosphorylation by G-protein-coupled receptor kinases, leading to a subsequent wave of G-protein-independent signaling involving β-arrestin (21). F-actin polymerization stimulated by CXCL12 WT was decreased in HCT116 cells in which β-arrestin-1 and -2 were genetically depleted ( (Fig. S5D) , suggesting G-proteins and arrestin play roles in monomer-induced actin rearrangement.
CXCL12 Monomers and Dimers Activate Discrete Signaling Profiles.
To uncover the mechanisms whereby CXCL12 suppresses tumor metastasis and regulates carcinoma cell migration, we defined the ability of CXCL12 variants to interact with its receptors CXCR4 and CXCR7 (22) . Whole cell radioligand binding assays indicated that CXCL12 WT and CXCL12 H25R each bound to CXCR4 and CXCR7 with high affinity, whereas CXCL12 2 preferentially interacted with CXCR4 ( Fig. 4 A and B) . Complementary radioligand displacement on cell membrane preparations showed that, relative to CXCR4, CXCL12 2 binds to Primary tumor size and (E) level of hepatic metastasis was quantified (RLU) using ex vivo imaging 6 weeks after implantation. Data in C-E are mean AE SEM, n ¼ 5-7 mice. Statistical significance was determined by oneway ANOVA followed by Tukey's posttest. *, P ≤ 0.05; **, P ≤ 0.01.
CXCR7 with approximately 1,000-fold lower affinity compared to CXCL12 WT (Fig. S6) , making CXCR7 an unlikely target for CXCL12 2 .
Dimeric CXCR4 activates heterotrimeric G-proteins, leading to inhibition of adenylyl cyclase and mobilization of intracellular calcium. As predicted, CXCL12 WT mobilized intracellular calcium in a pertussis toxin sensitive fashion, with CXCL12 H25R and CXCL12 2 each evoking comparable fluxes in calcium (Fig. 4C ).
Calcium mobilization was dose dependent and inhibited by CXCR4 specific inhibitors (Fig. S7) . We had previously demonstrated that CXCL12 binding to CXCR4 on colonic carcinoma cells inhibited forskolin-induced cAMP production (23) . To further assess G-protein activation, we next measured inhibition of forskolin-stimulated cAMP production using an Epac bioluminescence resonance energy transfer (BRET) sensor (24) . As shown in Fig. 4D , CXCL12 variants inhibited cAMP-dependent (D and E) Cells were exposed to 10 nM CXCL12 WT , CXCL12 H25R , CXCL12 2 , and 1,000 nM CXCL12 WT for 30 min, and F-actin polymerization and lamellipodia formation were visualized by Alexafluor-488 phalloidin staining. Lysophosphotidic acid (LPA) (1 μg∕mL) was a positive control. Average fluorescence intensity (AFI) per cell was determined using software at 600× magnification. Thirty single cells were randomly selected and examined per treatment in three independent experiments. Statistical significance was determined by unpaired Student's t test. *, P ≤ 0.05. activation of Epac, providing further evidence for Gαi activation via CXCR4.
Lastly, arrestin-dependent and -independent signaling through the G-protein -coupled receptor was examined. As shown in Fig. 4E and illustrated in Fig. S8 , CXCL12 H25R stimulated a slower increase in ERK1/2 phosphorylation relative to CXCL12 2 , which evoked a more rapid and transient activation. In agreement with those data, BRET analyses demonstrated that stimulation with CXCL12 WT and CXCL12 H25R elicited the dose-dependent (Fig. 4F ) and time-dependent (Fig. 4G ) recruitment of β-arrestin-2 to CXCR4. There was substantially less CXCL12 2 -induced recruitment of β-arrestin-2 (Fig. 4 F and G) . Nevertheless, as shown in Fig. 4H , each of the CXCL12 variants stimulated CXCR4 internalization. Thus, monomeric and dimeric chemokine functionally activate discrete signaling pathways through CXCR4.
CXCL12 Dimers Have Distinct Interactions with CXCR4. We next asked if the differential migration and signaling responses resulted from unique interactions between the CXCL12 variants and CXCR4. In the "two-step, two-site" model for chemokine receptor activation (25), CXCL12 binds first to the CXCR4 N terminus. Our prior work indicated that CXCR4 N terminus (CXCR4 1-38 ) bridges the CXCL12 dimer interface and forms contacts that are absent in the monomer, suggesting the oligomers interact differently with the receptor (17) . NMR measurements of CXCR4 dynamics indicate that residues 5-10 of the receptor are flexible in complex with CXCL12 2 but become more ordered when bound to CXCL12 H25R (Fig. 5A) . Based on these structural data, we speculated that oligomer-specific CXCR4 binding modes could lead to qualitatively different signaling.
In an NMR titration of ½U-15 N-labeled CXCR4 1-38 peptide with unlabeled CXCL12 WT , many residues shift in response to the addition of substoichiometric CXCL12 WT , but some peaks exhibited unusual behavior at higher chemokine concentrations (Fig. 5B) . In particular, the signals for S5 and I6 reversed direction and shifted back toward their original positions before broadening beyond detection. After initially moving to lower 1 H and 15 N frequencies, the T13 amide signal shifted in a different direction. In an equivalent titration using CXCL12 2 , only simple shift perturbations were observed, consistent with a single complex (17) . However, we showed previously that binding to CXCR4 1-38 promotes CXCL12 dimerization (26) . Thus, the biphasic progression of chemical shift perturbations induced by CXCL12 WT denotes the formation of distinct CXCL12-CXCR4 1-38 complexes during the titration as the CXCL12 equilibrium shifts from monomer to dimer. Together with the differences in backbone mobility, and as summarized in Fig. 5C , these data demonstrate that the CXCL12 monomer makes specific contacts with CXCR4 that are lost when CXCL12 dimerizes.
Discussion
Overexpression of CXCR4 has been correlated with tumor malignancy (6). Our refined model for chemokine-directed metastasis includes epigenetic silencing of the ligand that confers a leukocyte migratory phenotype to carcinoma cells that is diminished by reexpression of the suppressed chemokine (13) (14) (15) 25) . The purpose of our study was to test whether exogenous CXCL12 treatment would also reduce metastasis. In contrast to early studies focused largely on CXCR4 receptor antagonism, our data establish that exogenous CXCL12 is a potent inhibitor of colorectal and melanoma metastasis. Because CXCL12 exists in a monomer-dimer equilibrium, we also assessed the therapeutic potential of preferentially monomeric and constitutively dimeric CXCL12 variants. We demonstrated that CXCL12, independent of its oligomerization, reduced metastasis. In combination with our prior work, we have discovered that CXCL12 produced by cancer cells or administered in a preclinical setting provides a strong antimetastatic cue. Our work indicates that CXCL12 WT exists in a complex equilibrium in the presence of CXCR4 1-38 , consistent with our previous results (18) . Using CXCL12 H25R and CXCL12 2 , we isolated the equilibrium components and observed stable contacts between the CXCR4 N terminus and monomeric CXCL12 that are lost upon dimerization. CXCR4 forms constitutive homodimers in live cells (27) (28) . Thus, ligand dimerization might correspond to single-versus double-agonist occupancy of the dimeric receptor, with double occupancy by the forced dimeric ligand evoking an immotile cellular arrest response, as noted for other class A G-protein-coupled receptors (29) . If so, single versus double receptor-occupancy might indeed provide a general mechanism for the as yet unexplained ubiquitous biphasic dose-responses of chemotaxis, regardless of the capacity of the chemoattractant ligand to dimerize.
We previously demonstrated that CXCL12 H25R extended the chemotactic response to higher concentrations and that CXCL12 2 was unable to stimulate leukocyte migration (17) . With this report, we demonstrate that colon carcinoma cells follow a similar biphasic migration response driven almost exclusively by monomeric ligand. Examination of the receptors and signaling pathways regulating these opposing functions revealed that monomeric and dimeric chemokine bind to and drive internalization of CXCR4. Both ligands mobilize intracellular calcium and inhibit adenylyl cyclase signaling. Interestingly, CXCL12 H25R stimulated F-actin polymerization, mediated, at least in part, through β-arrestin, and evoked a prolonged phosphorylation of ERK1/2. In contrast, CXCL12 2 stimulated a rapid and transient increase in ERK1/2 with minimal, if any, recruitment of β-arrestin or induction of actin mobilization. Thus, a clue to the absent chemotactic response to CXCL12 2 may rest in altered β-arrestin-2 signaling. The requirement for β-arrestin-2 in CXCR4-mediated migration has been documented using knockout mice (30) , siRNA (31) , and in the context of hypermigratory CXCR4 mutations (32) . Depletion of both β-arrestin-1 and β-arrestin-2 significantly inhibited CXCL12 WT -or CXCL12 H25R -stimulated F-actin polymerization, suggesting arrestin was, in part, regulating migration. In contrast to arrestin knockdown, pertussis toxin abrogated HCT116 migration, calcium signaling, and cytoskeletal remodeling. Thus, we postulate dimer-induced signaling induces a nonmotile cellular idling response. The differential signaling activated by CXCL12 H25R and CXCL12 2 mirrors prior reports for the CCR7 ligands CCL19 and CCL21, as well as monomeric and dimeric forms of CXCL8 (33, 34) .
Differential activation of CXCR4 provides an exciting avenue for therapeutic intervention using biologic agonists tailored to the monomer or dimer. Chemokine-mediated inhibition of tumorigenesis has been attributed to trafficking of immune cells to the tumor (9, 35, 36) . Our work supports a cancer progression model in which locally produced CXCL12 limits the migration potential by either desensitizing cells to endocrine ligand or by exceeding the optimal level for chemotaxis, resulting in the absence of actin polymerization and cell migration characteristic of dimeric CXCL12 (13) (14) (15) . Alternatively, tumor-cell-produced CXCL12 limits spread of cells by nullifying chemokine gradients produced in distant tissues (13, 15) . Here, we show that administration of CXCL12 prevents metastasis of colonic carcinomas or murine melanomas lacking endogenous ligand expression. Although monomeric and dimeric ligands activate opposing cell migratory responses in vitro, each markedly inhibited metastasis in a preclinical animal model. Our data suggest CXCL12 interruption in metastasis results from formation of dimers at elevated concentrations activating distinct "cellular idling" signaling pathways, desensitizing tumor cell-expressed CXCR4, and/or ligandinduced disruption in chemoattractant gradients. Our data therefore fill the gap in the current model defining increased expression of CXCR4 as a key regulatory step in tumor metastasis and explain how pathologic silencing of the Cxcl12 gene during neoplasia (i) confers a metastatic phenotype to those cells and (ii) enhances metastasis through the loss of autocrine ligand formation that limits emigration. These data establish CXCL12 as a potential avenue for the next generation of biologic therapies that specifically target metastasis and suggest ligand administration is a viable neoadjuvant intervention in colon cancer and melanoma.
Materials and Methods
Cell Culture. HCT116 (CCL-247) and HT-29 (HTB-38) human colorectal carcinoma cells were purchased from ATCC and maintained as previously described (13) . The HCT double stable cell lines (GFP Luc or CXCL12 Luc) were defined in our prior report (15) .
Protein Expression and Purification. CXCL12 WT , CXCL12 2 , and CXCL12 H25R were expressed and purified as previously described (17, 18, 26, 37) .
Bioluminescence Imaging. HCT GFP-Luc cells (2 × 10 6 ) were suspended in 50 μL sterile phosphate-buffered saline (PBS) and implanted to the subserosal layer of the cecum in 8-week-old male SCID mice (cr-Prdkc scid , Charles River) using a Medical College of Wisconsin Institutional Animal Care and Use Committee approved protocol. CXCL12 Luc cells (2 × 10 6 ) were used as a control. Tumor burden was quantified as previously described (15) . See details in SI Materials and Methods.
Melanoma Metastasis. B16 murine melanoma cells in logarithmic phase of growth were premixed with vehicle or CXCL12 variant peptides in vitro and injected intravenously via the tail vein of mice. Prior to injection, cells were ≥90% viable as assessed by trypan blue exclusion. After 14 d, mice were euthanized and tumor burden quantified by in vitro luciferase assay as previously described (20) .
Chemotactic Migration. Transwell plates (8 μM pore size polycarbonate membrane, 6.5-mm diameter) were coated with 15 μg∕mL collagen for 30 min at 37°C (Corning Inc.). HCT116 cells were serum-starved 24 h and then released from the plate using cell dissociation buffer. Cells were collected, washed, and 50;000 cells∕100 μL plated in serum-free medium in the top chamber and chemokine in the bottom chamber. After 16 h, cells on the top transwell membrane were removed using a cotton swab, fixed, and stained with 4′,6-diamidino-2-phenylindole. Chemotaxis was quantified by counting the migrated cells on the lower surface of the membrane of at least three fields per chamber at 10× objective.
BRET Measurements. β-arrestin-2 recruitment to CXCR4 was measured by an intermolecular BRET assay performed as described previously (27, 38) . The values were corrected to net BRET by subtracting the background BRET signal obtained in cells transfected with the Rluc construct alone. Intracellular cAMP levels were measured using an intramolecular Epac BRET 2 sensor as described previously (24) . BRET signal was calculated as the ratio of light emitted by acceptor over the light emitted by donor. See details in SI Materials and Methods.
Flow Cytometry. Cells of the T-cell lymphoblastic line CEM were incubated with 100 nM of wild-type, monomeric, or dimeric CXCL12 in complete media at 37°C for the indicated time. Cells were washed in PBS and then incubated with phycoerythrin-conjugated mouse monoclonal antibody to CXCR4 (clone 12G5; R&D Systems) and fluorescence intensity measured by flow cytometry (FACS Calibur, BD Biosciences).
